RxDoctor Payments Data

Harold Cox, MD

Family Medicine · Montgomery, ALNPI 1114991072

Payments from drug & device makers

$12,270in general payments, 2019–2025

Across 800 payments — averaging $15.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$994
  • Pfizer$816
  • Amgen$710
  • Johnson & Johnson$696
  • Astellas Pharma US Inc$673
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$12,06598%
  • Education$2062%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)131$1,480
Novo Nordisk62$994
Pfizer60$816
Amgen43$710
Johnson & Johnson55$696
Astellas Pharma US Inc30$673
AstraZeneca26$490
Lilly USA, LLC31$452
Otsuka America Pharmaceutical, Inc.23$407
Bayer23$393
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC22$358
Sumitomo Pharma America, Inc.23$342
Novartis27$339
Esperion Therapeutics, Inc.19$263
Amarin Pharma, Inc.13$246
Merck15$232
GSK16$232
Nestle Healthcare Nutrition Inc.11$210
Sunovion Pharmaceuticals Inc.17$206
Boehringer Ingelheim13$183
Lundbeck LLC8$168
Takeda Pharmaceuticals U.S.A., Inc.6$159
Mylan Specialty L.p.9$156
Axsome Therapeutics, Inc.8$141
Biohaven Pharmaceuticals, Inc.8$139
Abbott7$131
Corcept Therapeutics7$119
Antares Pharma, Inc.6$110
Exact Sciences6$100
Biohaven Pharmaceutical Holding Company Ltd.5$95
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$90
Intuitive Surgical1$77
Dexcom, Inc.4$71
Ironwood Pharmaceuticals, Inc4$62
Neurocrine Biosciences, Inc.3$61
Shield Therapeutics Inc3$57
E.r. Squibb & Sons, L.L.C.3$57
Idorsia Pharmaceuticals US Inc3$51
IBSA Pharma Inc.3$49
Aytu Biopharma, Inc.3$48
Sanofi-aventis U.S. LLC3$44
Supernus Pharmaceuticals, Inc.3$42
Avanir Pharmaceuticals, Inc.2$38
Tolmar, Inc.2$37
Evoke Pharma, Inc.2$36
Adlon Therapeutics L.p.2$34
Arbor Pharmaceuticals, Inc.2$30
Inspire Medical Systems, Inc.1$30
Seqirus USA Inc1$25
Mannkind Corporation2$24
Ardelyx, Inc.1$24
Viatris Specialty LLC1$18
Ossur Americas, Inc.1$17
Inogen, Inc.1$17
Boston Scientific1$16
SK Life Science, Inc.1$16
Acadia Pharmaceuticals Inc1$15
UCB, Inc.1$15
Clarus Therapeutics Inc.1$15
Medicure Pharma Inc.1$14

How this compares

$12,270 in reported general payments places this provider in the 90th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$157,721
Medicare patients
400
Services billed
1,894

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban457$311,684
OzempicSemaglutide243$275,704
JardianceEmpagliflozin327$251,044
Prolastin CAlpha-1-Proteinase Inhibitor11$147,235
FarxigaDapagliflozin Propanediol150$132,123
MounjaroTirzepatide84$87,901
XareltoRivaroxaban156$87,292
RexultiBrexpiprazole109$85,704
RybelsusSemaglutide78$85,341
Trelegy ElliptaFluticasone/Umeclidin/Vilanter91$85,019
JanuviaSitagliptin Phosphate137$66,523
MyrbetriqMirabegron134$58,153
TrulicityDulaglutide53$56,580
EntrestoSacubitril/Valsartan79$40,425
LinzessLinaclotide52$38,639

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$994$361,045321 claims
PfizerEliquis, Abrysvo$816$324,251497 claims
Boehringer IngelheimJardiance, Tradjenta$183$267,350376 claims
Lilly USA, LLCMounjaro, Trulicity$452$144,481137 claims
AstraZenecaFarxiga, Lokelma$490$142,327166 claims
MerckJanuvia, Janumet Xr$232$87,662176 claims
Johnson & JohnsonXarelto$696$87,292156 claims
Otsuka America Pharmaceutical, Inc.Rexulti$407$85,704109 claims
GSKTrelegy Ellipta$232$85,01991 claims
Astellas Pharma US IncMyrbetriq$673$58,153134 claims
AbbVieLinzess, Creon$1,480$52,67863 claims
NovartisEntresto$339$40,42579 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →